ClinicalTrials.gg
CompletedNCT04325620Updated Nov 9, 2022

Safety to Evaluate the Efficacy and Safety of HIP1601 in Patients With Non Erosive Reflux Disease

A Phase 3 interventional study of HIP1601 and HGP1805 in Non-erosive Gastroesphageal Reflux Disease, sponsored by Hanmi Pharmaceutical Company Limited. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-11-09.

Sponsored by Hanmi Pharmaceutical Company Limited · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 9 months after the study started (first participant enrolled Jun 2019, registered Mar 2020).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
208
Allocation
Randomized
Ages
19 Years to 75 Years
Sex
All
01

Study summary

The purpose of this study is to investigate the safety and clinical efficacy of HIP1601 in patients with Non-erosive gastroesphageal reflux disease.

Read the detailed description

A Multicenter, Randomized, Parallel, Double-Blinded, Placebo-controlled Phase Ⅲ Study to Compare Efficacy and Safety of HIP1601 in Patients with Non-Erosive Gastroesophageal Reflux Disease(NERD)

02

Conditions studied

  • Non-erosive Gastroesphageal Reflux Disease
03

In context

Lead sponsor

Hanmi Pharmaceutical Company Limited is the lead sponsor of 191 studies on the registry; 12 are open to participants now.

Of its 11 completed or terminated interventional studies of FDA-regulated products, 6 (55%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 19≤ age ≤ 75
  • Patients who were not observed mucosal break('not present') according to the LA classification(LA grade) on the EGDEsophago-Gastro-Duodenoscopy
  • Patients who had experienced major symptom within 3 months Patients experienced heartburn or acid regurgitation within 7 days of screening day
  • Patients who had experienced major symptom within 7 days before randomization. Entry into study also required that patients had experienced at least mild symptoms on at least 2 days/week or at least moderate symptoms on at least 1 day/week based on RDQ
  • Patients understood the consents and purpose of this trial and signed consent form

Exclusion criteria

Exclusion Criteria:

  • Patients who have erosive GERD, Barrett's esophagus(other significant dysplasia of esophagus), gastroesophageal varicose veins, active peptic ulcer, gastrointestinal bleeding or malignant GI tumor confirmed by endoscopy
  • Patients who have a history of gastric or gastroesophageal surgery
  • Patients who have Zollinger-Ellison syndrome, eosinophilic esophagitis, primary esophageal motility disorder, acute upper gastrointestinal bleeding, Functional dyspepsia, IBS, IBD within 3 months before Visit 1
  • Patients with liver, kidney, nervous system, respiratory, endocrine, hematologic, cardiovascular, urinary system disease.
  • Patients Has a severe liver disorder( or ALT level exceeds 3 times more than normal upper range at Visit 1)
  • Has a clinically significant renal failure( eGFR ≤ 59 mL/min/1.73m2 or Serum creatinine >2.0mg/dL at Visit 1)
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
208 participants (actual)

Study arms

  • Experimental
    HIP1601 Amg

    The participants will receive tretment of HIP1601 Amg, orally, once daily for 4weeks.

    Drug: HIP1601

  • Placebo comparator
    HGP1805

    The participants will receive tretment of HGP1805(Placebo of HIP1601), orally, once daily for 4weeks.

    Drug: HGP1805

Interventions

  • HIP1601

  • DrugHGP1805

    Placebo of HIP1601

06

What researchers measure

Primary outcomes

  1. Percentage of patients with complete resolution of major symptoms at 4-week

    Complete resolution is defined as no episodes of symptom during the last 7 days of treatment.

    Time frame: 4 week

Secondary outcomes

  1. Percentage of patients with complete resolution of major symptoms at 2-week

    Complete resolution is defined as no episodes of symptom during the last 7 days of treatment

    Time frame: 2 week

  2. Frequency and Severity of Reflux disease symptom assessment using Reflux Disease Questionnaire(RDQ)

    RDQ frequncy and severity score is 0 to 5 point scale, high score mean a worse outcome.

    Time frame: 2, 4 week

  3. Time to complete resolution of major symptoms

    defined as time to the first day of complete resolution

    Time frame: 4 week

  4. Resolution rate of major symptoms of first 7 days

    defined as first of 7 days with no episodes of symptom using subject's diary

    Time frame: 1 week

  5. Major symptoms-Free days

    Major symptoms-Free days mean rate of days that symtom's severity score is '0' using subject's diary

    Time frame: 1, 4 week

  6. Quality of Life assessment using Patient Assessment of upper Gastrointestinal disorders-Quality of Life(PAGI-QoL)

    PAGI-QoL total score is 0 to 30 point scale, high score mean a better outcome.

    Time frame: 4 week

  7. Proportion of rescue medication amounts

    Use of rescue medication

    Time frame: 4 week

07

Study locations

1 site
  • Seoul National University Bundang Hospital
    Seongnam, Gyeonggi-do 13620, Korea, Republic of
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2019 to primary completion in Aug 2020, 13 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 26, 2020
First posted
Mar 27, 2020
StartActual
Jun 10, 2019
Primary completionActual
Aug 3, 2020
CompletionActual
Aug 3, 2020
Last update
Nov 9, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 9, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04325620
Responsible party
Sponsor
First posted
Mar 27, 2020
Start date
Jun 10, 2019
Primary completion
Aug 3, 2020
Completion
Aug 3, 2020
Last update
Nov 9, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Esomeprazole

Start the discussion